Key Points
- Stryker VP Robert Fletcher sold 4,544 shares on May 28 at an average price of $306.87, a transaction worth about $1.39 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- The company’s latest quarterly results missed Wall Street expectations, with EPS of $2.60 versus an estimated $2.98 and revenue of $6.02 billion versus $6.34 billion expected. Stryker still posted 2.6% year-over-year revenue growth and guided FY 2026 EPS to 14.90-15.10.
- Stryker announced a quarterly dividend of $0.88 per share, payable July 31 to shareholders of record on June 30. That works out to an annualized dividend of $3.52 and a 1.2% yield.
Stryker Corporation (NYSE:SYK - Get Free Report) VP Robert Fletcher sold 4,544 shares of the company's stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Stryker Trading Down 0.6%
Shares of NYSE SYK opened at $305.73 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The business has a fifty day simple moving average of $321.82 and a two-hundred day simple moving average of $348.15. The firm has a market cap of $117.21 billion, a PE ratio of 35.39, a price-to-earnings-growth ratio of 1.94 and a beta of 0.80. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87.
Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.
Stryker Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker's payout ratio is 40.74%.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on SYK shares. UBS Group decreased their target price on Stryker from $400.00 to $380.00 and set a "neutral" rating for the company in a research report on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research report on Friday, May 1st. Citigroup cut their price target on Stryker from $420.00 to $385.00 and set a "buy" rating on the stock in a report on Tuesday, April 7th. Robert W. Baird set a $385.00 price target on Stryker in a report on Friday, May 1st. Finally, Barclays cut their price target on Stryker from $469.00 to $394.00 and set an "overweight" rating on the stock in a report on Monday, May 4th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $395.48.
Get Our Latest Report on SYK
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in SYK. VanderPol Investments L.L.C. lifted its stake in shares of Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock valued at $732,000 after purchasing an additional 28 shares during the period. Rossby Financial LCC lifted its stake in shares of Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock valued at $159,000 after purchasing an additional 28 shares during the period. KCM Investment Advisors LLC lifted its stake in shares of Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock valued at $653,000 after purchasing an additional 28 shares during the period. Lantz Financial LLC lifted its stake in shares of Stryker by 5.0% in the 3rd quarter. Lantz Financial LLC now owns 608 shares of the medical technology company's stock valued at $225,000 after purchasing an additional 29 shares during the period. Finally, Stonebridge Capital Advisors LLC lifted its stake in shares of Stryker by 0.4% in the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company's stock valued at $2,661,000 after purchasing an additional 29 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.
About Stryker
(
Get Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
